Search

Your search keyword '"Gooderham, M."' showing total 289 results

Search Constraints

Start Over You searched for: Author "Gooderham, M." Remove constraint Author: "Gooderham, M."
289 results on '"Gooderham, M."'

Search Results

251. Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study.

252. Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome.

253. Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis.

254. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

255. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.

256. Psoriasis, Depression, and Suicidality.

257. An Open Letter to Health Canada.

258. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.

259. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).

260. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.

261. Review of Systemic Treatment Options for Adult Atopic Dermatitis.

262. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.

264. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.

265. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.

266. A Review of Psoriasis, Therapies, and Suicide.

267. Management of scalp psoriasis: current perspectives.

268. Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.

269. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).

270. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).

271. The psychosocial impact of hidradenitis suppurativa.

272. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.

273. Apremilast in the treatment of psoriasis and psoriatic arthritis.

274. Methylisothiazolinone testing at 2000 ppm: a prevalent sensitizer for allergic contact dermatitis.

275. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.

276. Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12-17 years of age.

277. A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin.

278. Small molecules: an overview of emerging therapeutic options in the treatment of psoriasis.

279. Rosacea: update on management and emerging therapies.

280. Ingenol mebutate: an introduction.

281. Bedbugs: an update on recognition and management.

282. Rosacea and its topical management.

283. Use of hyaluronic acid for soft tissue augmentation of HIV-associated facial lipodystrophy.

284. Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin.

285. Sun and the skin: evaluation of a sun awareness program for elementary school students.

286. Impact of a sun awareness curriculum on medical students' knowledge, attitudes, and behaviour.

287. A soy protein isolate rich in genistein and daidzein and its effects on plasma isoflavone concentrations, platelet aggregation, blood lipids and fatty acid composition of plasma phospholipid in normal men.

288. Quantification of the carcinogens 2-amino-3,8-dimethyl- and 2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in food using a combined assay based on gas chromatography-negative ion mass spectrometry.

289. A clinical approach to alcoholism.

Catalog

Books, media, physical & digital resources